Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice

Objective—Chemokines and their receptors are crucially involved in the development of atherosclerotic lesions by directing monocyte and T cell recruitment. The CC-chemokine receptors 1 (CCR1) and 5 (CCR5) expressed on these cells bind chemokines implicated in atherosclerosis, namely CCL5/RANTES. Although general blockade of CCL5 receptors reduces atherosclerosis, specific roles of CCR1 and CCR5 have not been unequivocally determined. Methods and Results—We provide two independent lines of investigation to dissect the effects of Ccr1 and Ccr5 deletion in apolipoprotein E–deficient (ApoE−/−) mice in a collaboration between Aachen/Germany and Geneva/Switzerland. Different strains of ApoE−/−Ccr5−/− mice, ApoE−/−Ccr1−/− mice or respective littermates, were fed a high-fat diet for 10 to 12 weeks. Plaque areas were quantified in the aortic roots and thoracoabdominal aortas. Concordantly, both laboratories found that lesion formation was reduced in ApoE−/−Ccr5−/− mice. Plaque quality and immune cells were assessed by immunohistochemistry or mRNA analysis. Whereas lesional macrophage content, aortic CD4, and Th1-related Tim3 expression were reduced, smooth muscle cell (SMC) content and expression of interleukin-10 in plaques, lesional SMCs, and splenocytes were elevated. Protection against lesion formation by Ccr5 deficiency was sustained over 22 weeks of high-fat diet or over 26 weeks of chow diet. Conversely, plaque area, T cell, and interferon-&ggr; content were increased in ApoE−/−Ccr1−/− mice. Conclusion—Genetic deletion of Ccr5 but not Ccr1 in ApoE−/− mice protects from diet-induced atherosclerosis, associated with a more stable plaque phenotype, reduced mononuclear cell infiltration, Th1-type immune responses, and increased interleukin-10 expression. This corroborates CCR5 as a promising therapeutic target.

[1]  F. Mach,et al.  Leukocyte recruitment in atherosclerosis: Potential targets for therapeutic approaches? , 2006, Cellular and Molecular Life Sciences CMLS.

[2]  C. Weber Killing two birds with one stone: targeting chemokine receptors in atherosclerosis and HIV infection. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[3]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[4]  Atsushi Mizoguchi,et al.  Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1+ Lymphocyte-Associated Th2-Type Immune Response in the Intestine1 , 2000, The Journal of Immunology.

[5]  Michael Ginsberg,et al.  Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Uguccioni,et al.  Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. , 2003, Blood.

[7]  Z. Prohászka,et al.  Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. , 2001, Atherosclerosis.

[8]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[9]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[10]  B. Rollins,et al.  Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[11]  V. Álvarez,et al.  Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction , 2001, Genes and Immunity.

[12]  R. Horuk,et al.  Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. , 2001, Blood.

[13]  U. Andersson,et al.  Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. , 1999, Atherosclerosis.

[14]  P. Sharp,et al.  Involvement of CCR5 in the passage of Th1‐type cells across the blood‐retina barrier in experimental autoimmune uveitis , 2006, Journal of leukocyte biology.

[15]  J. Witztum,et al.  T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Balling,et al.  Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5‐deficient mice , 2004, European journal of immunology.

[17]  A. Tedgui,et al.  Role of Bone Marrow–Derived CC-Chemokine Receptor 5 in the Development of Atherosclerosis of Low-Density Lipoprotein Receptor Knockout Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Zernecke,et al.  Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  R. Alon,et al.  Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.

[20]  Christian Weber,et al.  Platelet Microparticles: A Transcellular Delivery System for RANTES Promoting Monocyte Recruitment on Endothelium , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[21]  F. Mach,et al.  Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.

[22]  J. Flores,et al.  Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non‐obese diabetic mice , 2004, European journal of immunology.

[23]  Weixin Zhao,et al.  Human Vascular Smooth Muscle Cells Possess Functional CCR5* , 2000, The Journal of Biological Chemistry.

[24]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[25]  N. Maeda,et al.  CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. , 2003, Atherosclerosis.

[26]  A. Zernecke,et al.  Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. , 2006, Blood.

[27]  F. Mach,et al.  Differential Expression Patterns of Proinflammatory and Antiinflammatory Mediators During Atherogenesis in Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[28]  H. Broxmeyer,et al.  Impaired Host Defense, Hematopoiesis, Granulomatous Inflammation and Type 1–Type 2 Cytokine Balance in Mice Lacking CC Chemokine Receptor 1 , 1997, The Journal of experimental medicine.

[29]  L. Demer,et al.  Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. , 1996, The Journal of clinical investigation.

[30]  K. Ley,et al.  RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium , 2001, Circulation.

[31]  A. Tedgui,et al.  Chemokine Receptor CCR1 Disruption in Bone Marrow Cells Enhances Atherosclerotic Lesion Development and Inflammation in Mice , 2005, Molecular medicine.

[32]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[33]  T. Schall,et al.  Local expression of inflammatory cytokines in human atherosclerotic plaques. , 1994, Journal of atherosclerosis and thrombosis.

[34]  W. Kuziel,et al.  The CC Chemokine Receptor 5 Is Important in Control of Parasite Replication and Acute Cardiac Inflammation following Infection with Trypanosoma cruzi , 2006, Infection and Immunity.

[35]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[36]  Qingbo Xu Role of heat shock proteins in atherosclerosis. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[37]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[38]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[39]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[40]  H. Fujiwara,et al.  HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.